Rezultati pretraživanja
  1. 8. kol 2019.

    Importantly, we found a region of density that is present in the active structure but not the inactive structure that is the right size for FDA-approved drugs for certain forms of hypertension. 7/n

    Prikaži ovu nit
  2. pts frequently receive After our previous work on between inh and or , happy to share our last work on the potential between and

    Prikaži ovu nit
  3. 10. ruj 2018.

    Important study by 🇨🇦 colleague Lisa Mielniczuk, editorial by showing improved RV form / function: will we see the same w/ in the enrolling pts w/ ?

  4. 8. tra 2013.

    NDA for Granted Priority Review by

  5. has raced to the FDA with its application for , a promising candidate for pulmonary hypertension.....

  6. 4. lis 2018.

    Dr. Distler's presents Phase 2 data of Riociguat in early . Like previous 2 trials, skin score was no different in Riociguat & Placebo group but were clear trends favoring for retarding disease progression.

  7. 17. kol 2019.
  8. 13. lip 2019.

    En esclerosis sistémica el podría tener efectos positivos en función pulmonar (énfasis en el PODRÍA)

  9. 9. tra 2019.

    Very important findings about the potential role of CYP1A enzymes (regulated by immunemodulatory transcription factor ) in rationalizing interparient variability of drug exposure. as the tip of the iceberg of a more general & underappreciated effect?

  10. Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. .

  11. 25. sij 2019.

    Smaller right heart size and better right ventricular function have been observed in individuals with or undergoing long-term treatment.

  12. Prof. Oliver Distler interviewed on the results of the in . Head to youtube for the full interview.

  13. 21. kol 2016.

    not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias

  14. 30. sij 2016.

    7 días... habrá que crear el templo a pues es patrón ya de los .

  15. 4. ruj 2015.

    Abstract from new supplement : The clinical development of modulators, and

  16. 10. lip 2015.
  17. 8. pro 2014.

    Scottish Medicines Consortium - approved 4 restricted use in CTEPH @BayerHealthCare

  18. 14. stu 2014.
  19. 11. stu 2014.

    En México única terapia en el mundo y la de tipo crónico no operable resistente/recurrente

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.